Padeliporfin di-potassium

N/A

Report date: 2023/12/21 14:53:39
NMEFirst In Class

Base Information

Drug NamePadeliporfin di-potassium
Drug Alias NamePadeliporfin potassiumPalladium bacteriopheophorbide monolysine taurineStakel(ImPact Biotech)Padeliporfin VTP(ImPact Biotech)Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular disrupting agents (VDA)Photosensitizers
TargetsNot applicable
Therapy Area/IndicationsChoroidal NeovascularizationMacular DegenerationKidney Neoplasms +[11] 
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/11/10
Country/TerritoryBelgiumCanadaPanama +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSteba Biotech Sa
China Registration ClassN/A

Develop Information

Active CompaniesMaastricht UniversityImpact Biotech LtdSteba Biotech Sa
Inactive CompaniesSteba FranceUniversity Of Oxford
Active IndicationsProstatic NeoplasmsLung NeoplasmsStomach Neoplasms +[6] 
Inactive IndicationsChoroidal NeovascularizationMacular DegenerationKidney Neoplasms +[5] 

Other Information

ATC CodeL01XD07
Related LinksDrugBank